Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C21H20FN7.C4H4O4 |
Molecular Weight | 505.501 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)\C=C/C(O)=O.C[C@H](NC1=NC(NC2=NC=CN=C2)=CC(=C1)C3=CN(C)N=C3)C4=CC=C(F)C=C4
InChI
InChIKey=OVAGJAAQMBYZDS-FXSDFHGDSA-N
InChI=1S/C21H20FN7.C4H4O4/c1-14(15-3-5-18(22)6-4-15)26-19-9-16(17-11-25-29(2)13-17)10-20(27-19)28-21-12-23-7-8-24-21;5-3(6)1-2-4(7)8/h3-14H,1-2H3,(H2,24,26,27,28);1-2H,(H,5,6)(H,7,8)/b;2-1-/t14-;/m0./s1
Molecular Formula | C21H20FN7 |
Molecular Weight | 389.4288 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Molecular Formula | C4H4O4 |
Molecular Weight | 116.0722 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Optical Activity | NONE |
NS-018 is a potent inhibitor of Janus kinase 2 (JAK2) enzyme activity and Src-family kinases. It was developed as an oral therapy for the treatment of myelofibrosis. Overall NS-018 has been used in trials studying the treatment of primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia. NS-018 is a highly active JAK2 inhibitor, with an IC50 of 0.72 nM, 46-, 54-, and 31-fold selectivity for JAK2 over JAK1 (IC50, 33 nM), JAK3 (IC50, 39 nM), and Tyk2 (IC50, 22 nM). NS-018 also inhibits Src-family kinases, especially SRC and FYN, and weakly inhibits ABL and FLT3 with 45- and 90-fold selectivity for JAK2, respectively. NS-018 shows potent inhibitory activity against cell lines JAK2V617F or MPLW515L mutations or the TEL-JAK2 fusion gene.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2971 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22829185 |
0.72 nM [IC50] | ||
Target ID: CHEMBL3553 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22829185 |
22.0 nM [IC50] | ||
Target ID: CHEMBL2835 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22829185 |
33.0 nM [IC50] | ||
Target ID: CHEMBL2148 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22829185 |
39.0 nM [IC50] |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27479177
In this phase I, dose-escalation portion of a phase I/II study, patients with myelofibrosis received oral NS-018 in continuous 28-day cycles. Once daily NS-018 at 300 mg was chosen as the phase II study dose based on improved tolerability compared with higher doses.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22829185
NS-018 is a highly active JAK2 inhibitor, with an IC50 of 0.72 nM, 46-, 54-, and 31-fold selectivity for JAK2 over JAK1 (IC50, 33 nM), JAK3 (IC50, 39 nM), and Tyk2 (IC50, 22 nM). NS-018 shows potent inhibitory activity against cell lines JAK2V617F or MPLW515L mutations or the TEL-JAK2 fusion gene (expressing a constitutively activated JAK2) with IC50 of 11-120 nM, but has only minimal cytotoxicity against most other hematopoietic cell lines that have no constitutively activated JAK2.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:12:30 GMT 2023
by
admin
on
Sat Dec 16 11:12:30 GMT 2023
|
Record UNII |
8P0KTT2T1Z
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
916522
Created by
admin on Sat Dec 16 11:12:30 GMT 2023 , Edited by admin on Sat Dec 16 11:12:30 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
56599590
Created by
admin on Sat Dec 16 11:12:30 GMT 2023 , Edited by admin on Sat Dec 16 11:12:30 GMT 2023
|
PRIMARY | |||
|
1354799-87-3
Created by
admin on Sat Dec 16 11:12:30 GMT 2023 , Edited by admin on Sat Dec 16 11:12:30 GMT 2023
|
PRIMARY | |||
|
100000183577
Created by
admin on Sat Dec 16 11:12:30 GMT 2023 , Edited by admin on Sat Dec 16 11:12:30 GMT 2023
|
PRIMARY | |||
|
8P0KTT2T1Z
Created by
admin on Sat Dec 16 11:12:30 GMT 2023 , Edited by admin on Sat Dec 16 11:12:30 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|